$3.45
+0.59
(+20.63%)▲
14.17%
Downside
Day's Volatility :15.16%
Upside
1.15%
74.19%
Downside
52 Weeks Volatility :80.3%
Upside
23.67%
Period | Personalis Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 126.09% | 6.5% | 0.0% |
6 Months | 108.76% | 7.1% | 0.0% |
1 Year | 28.25% | 9.8% | 0.0% |
3 Years | -86.34% | 14.2% | -20.2% |
Market Capitalization | 147.5M |
Book Value | $2.35 |
Earnings Per Share (EPS) | -1.9 |
Wall Street Target Price | 4.6 |
Profit Margin | -124.9% |
Operating Margin TTM | -96.7% |
Return On Assets TTM | -23.86% |
Return On Equity TTM | -58.92% |
Revenue TTM | 74.1M |
Revenue Per Share TTM | 1.51 |
Quarterly Revenue Growth YOY | 3.5000000000000004% |
Gross Profit TTM | 13.4M |
EBITDA | -77.9M |
Diluted Eps TTM | -1.9 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.41 |
EPS Estimate Next Year | -1.33 |
EPS Estimate Current Quarter | -0.41 |
EPS Estimate Next Quarter | -0.39 |
What analysts predicted
Upside of 33.33%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 37.8M | ↑ 302.15% |
Net Income | -19.9M | ↓ 15.73% |
Net Profit Margin | -52.64% | ↑ 198.59% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 65.2M | ↑ 72.62% |
Net Income | -25.1M | ↑ 26.14% |
Net Profit Margin | -38.47% | ↑ 14.17% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 78.6M | ↑ 20.61% |
Net Income | -41.3M | ↑ 64.57% |
Net Profit Margin | -52.49% | ↓ 14.02% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 85.5M | ↑ 8.7% |
Net Income | -65.2M | ↑ 58.01% |
Net Profit Margin | -76.29% | ↓ 23.8% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 65.0M | ↓ 23.92% |
Net Income | -113.3M | ↑ 73.73% |
Net Profit Margin | -174.2% | ↓ 97.91% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 73.5M | ↑ 12.97% |
Net Income | -108.3M | ↓ 4.43% |
Net Profit Margin | -147.38% | ↑ 26.82% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 16.7M | ↑ 12.55% |
Net Income | -31.1M | ↑ 17.27% |
Net Profit Margin | -185.79% | ↓ 7.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.9M | ↑ 12.79% |
Net Income | -28.7M | ↓ 7.75% |
Net Profit Margin | -151.96% | ↑ 33.83% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 16.7M | ↓ 11.46% |
Net Income | -24.0M | ↓ 16.41% |
Net Profit Margin | -143.45% | ↑ 8.51% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.2M | ↑ 9.27% |
Net Income | -29.1M | ↑ 21.47% |
Net Profit Margin | -159.47% | ↓ 16.02% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 19.7M | ↑ 7.83% |
Net Income | -26.6M | ↓ 8.64% |
Net Profit Margin | -135.12% | ↑ 24.35% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 19.5M | ↓ 0.76% |
Net Income | -13.0M | ↓ 51.22% |
Net Profit Margin | -66.42% | ↑ 68.7% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 41.7M | ↑ 24.15% |
Total Liabilities | 148.1M | ↑ 17.35% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 157.3M | ↑ 277.47% |
Total Liabilities | 50.6M | ↓ 65.82% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 244.8M | ↑ 55.66% |
Total Liabilities | 49.9M | ↓ 1.39% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 396.5M | ↑ 61.95% |
Total Liabilities | 86.2M | ↑ 72.81% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 292.7M | ↓ 26.18% |
Total Liabilities | 74.6M | ↓ 13.53% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 225.1M | ↓ 23.1% |
Total Liabilities | 95.7M | ↑ 28.29% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 292.7M | ↓ 7.92% |
Total Liabilities | 74.6M | ↓ 1.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 272.2M | ↓ 7.01% |
Total Liabilities | 78.5M | ↑ 5.35% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 249.0M | ↓ 8.5% |
Total Liabilities | 73.0M | ↓ 7.12% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 226.6M | ↓ 9.0% |
Total Liabilities | 75.4M | ↑ 3.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 225.1M | ↓ 0.68% |
Total Liabilities | 95.7M | ↑ 26.82% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 195.3M | ↓ 13.25% |
Total Liabilities | 74.6M | ↓ 22.03% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.6M | ↑ 1821.38% |
Investing Cash Flow | -7.9M | ↑ 52.23% |
Financing Cash Flow | -591.0K | ↓ 103.6% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -18.1M | ↓ 424.28% |
Investing Cash Flow | -81.6M | ↑ 938.96% |
Financing Cash Flow | 134.9M | ↓ 22933.84% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -42.7M | ↑ 136.06% |
Investing Cash Flow | -65.1M | ↓ 20.15% |
Financing Cash Flow | 121.3M | ↓ 10.14% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -70.8M | ↑ 66.06% |
Investing Cash Flow | -60.1M | ↓ 7.79% |
Financing Cash Flow | 169.7M | ↑ 39.94% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -70.2M | ↓ 0.84% |
Investing Cash Flow | 52.5M | ↓ 187.46% |
Financing Cash Flow | 1.4M | ↓ 99.2% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.8M | ↑ 13.53% |
Investing Cash Flow | 21.9M | ↑ 101.84% |
Financing Cash Flow | 511.0K | ↓ 32.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -15.7M | ↓ 6.07% |
Investing Cash Flow | 13.8M | ↓ 36.88% |
Financing Cash Flow | 925.0K | ↑ 81.02% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.4M | ↓ 33.86% |
Investing Cash Flow | 19.5M | ↑ 41.73% |
Financing Cash Flow | 925.0K | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.7M | ↑ 60.18% |
Investing Cash Flow | -8.6M | ↓ 144.02% |
Financing Cash Flow | 290.0K | ↓ 68.65% |
Sell
Neutral
Buy
Personalis Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Personalis Inc | 141.35% | 108.76% | 28.25% | -86.34% | -85.2% |
![]() Idexx Laboratories, Inc. | -3.67% | -10.34% | -15.37% | -31.35% | 65.77% |
![]() Agilent Technologies Inc. | 1.42% | 3.05% | 5.07% | -10.16% | 94.22% |
![]() Thermo Fisher Scientific, Inc. | 6.51% | 8.62% | 3.5% | 12.36% | 106.99% |
![]() Danaher Corp. | 6.51% | 15.92% | 1.97% | -6.92% | 89.83% |
![]() Iqvia Holdings Inc. | 10.0% | 7.5% | 0.14% | -6.07% | 45.29% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Personalis Inc | NA | NA | NA | -1.41 | -0.59 | -0.24 | NA | 2.35 |
![]() Idexx Laboratories, Inc. | 45.67 | 45.67 | 4.75 | 11.06 | 0.72 | 0.23 | NA | 18.93 |
![]() Agilent Technologies Inc. | 31.63 | 31.63 | 2.7 | 5.2 | 0.21 | 0.08 | 0.01 | 21.31 |
![]() Thermo Fisher Scientific, Inc. | 35.72 | 35.72 | 2.81 | 21.71 | 0.14 | 0.05 | 0.0 | 120.87 |
![]() Danaher Corp. | 48.76 | 48.76 | 3.13 | 6.99 | 0.08 | 0.04 | 0.0 | 68.92 |
![]() Iqvia Holdings Inc. | 30.13 | 30.13 | 1.33 | 11.19 | 0.23 | 0.05 | NA | 36.83 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Personalis Inc | Buy | $147.5M | -85.2% | NA | -124.9% |
![]() Idexx Laboratories, Inc. | Buy | $38.8B | 65.77% | 45.67 | 23.26% |
![]() Agilent Technologies Inc. | Buy | $38.9B | 94.22% | 31.63 | 18.84% |
![]() Thermo Fisher Scientific, Inc. | Buy | $219.4B | 106.99% | 35.72 | 14.2% |
![]() Danaher Corp. | Buy | $191.9B | 89.83% | 48.76 | 17.83% |
![]() Iqvia Holdings Inc. | Buy | $42.3B | 45.29% | 30.13 | 9.39% |
Insights on Personalis Inc
Revenue is down for the last 2 quarters, 19.67M → 19.52M (in $), with an average decrease of 0.8% per quarter
Netprofit is up for the last 3 quarters, -29.09M → -12.96M (in $), with an average increase of 57.2% per quarter
In the last 3 years, Personalis Inc has experienced a drawdown of -86.3%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 76.1%
ARK Investment Management LLC
BlackRock Inc
Vanguard Group Inc
Renaissance Technologies Corp
Acadian Asset Management LLC
Sumitomo Mitsui Trust Holdings Inc
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Organization | Personalis Inc |
Employees | 223 |
CEO | Mr. Christopher M. Hall |
Industry | Biotechnology |
A Spac I Acquisition Corp
$3.45
+20.63%
Keyarch Acquisition Corp
$3.45
+20.63%
Connexa Sports Technologies Inc
$3.45
+20.63%
Us Value Etf
$3.45
+20.63%
First Wave Biopharma Inc
$3.45
+20.63%
Global X Msci Next Emerging
$3.45
+20.63%
Fat Projects Acquisition Corp
$3.45
+20.63%
Capital Link Global Fintech
$3.45
+20.63%
Applied Uv Inc
$3.45
+20.63%